Methylprednisolone for Moderate to Severe Traumatic Brain Injury
Key facts
- Who runs it
- Zhangjiagang First People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 520 people, planned
- Started
- 29 Mar 2026
- Expected to end
- 31 Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Placebo
- Methylprednisolone (MP)
- Record updated
- 22 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age18-65 years
- Patients with moderate-to-severe traumatic brain injury whose Glasgow Coma Scale (GCS) score at admission is4-12
- Study drug must be initiated within12 hours after injury
- Imaging (CT) demonstrates cerebral contusion, or cerebral contusion with intracerebral hematoma
- Written informed consent obtained from the subject or legally authorized representative
Who cannot take part
- Known hypersensitivity to corticosteroids or any contraindication to their use
- Patients with systemic infectious diseases
- Patients with a confirmed diagnosis of peptic ulcer
- Patients with a confirmed diagnosis of systemic autoimmune diseases
- Any condition that, in the investigator's opinion, renders the patient unsuitable for this study
- History of diabetes mellitus requiring pharmacological treatment, or capillary blood glucose<2.8 mmol/L or >22.2 mmol/L
- Shock at admission (systolic blood pressure<90 mmHg for more than30 minutes)
- Pregnant or lactating women
- Participation in another clinical trial within the past3 months
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if standard-dose methylprednisolone sodium succinate can improve neurological recovery and safety in adults with moderate to severe traumatic brain injury (TBI). The main questions it aims to answer are:
Read full original descriptionShow less
1. Does adding a 5-day course of methylprednisolone improve overall long-term neurological outcome compared with placebo? 2. Does methylprednisolone reduce 6-month mortality or increase the proportion of patients with good neurological recovery? 3. What medical problems do participants experience when receiving methylprednisolone? Researchers will compare methylprednisolone sodium succinate (2 mg/kg/day intravenously for 5 days) with a matching placebo to see if the steroid improves outcomes beyond standard TBI care.
Participants will:
1. Receive either methylprednisolone or placebo once daily for 5 days, added to guideline-directed standard care. 2. Undergo CT scans and neuro-examinations during hospitalization. 3. Return for follow-up visits at 1 month and 6 months after injury for neurological assessments, safety checks, and questionnaires.
The 2 groups in the trial
- methylprednisoloneTreatment being tested
Treatment: Methylprednisolone (MP)
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Methylprednisolone Sodium Succinate Injection in Patients With Moderate to Severe Traumatic Brain Injury
- Criteria questions
- Built from NCT07180277, who can take part
- Record updated
- 22 September 2026